Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

PURPOSE: In MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2− metastatic breast cancer (MBC). To help interpret these results and put in clinical context, we compared over...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Main Authors: Rugo, Hope S., Dieras, Veronique, Cortes, Javier, Patt, Debra, Wildiers, Hans, O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Carter, Gebra Cuyun, Sheffield, Kristin M., Li, Li, Andre, Valerie A. M., Li, Xiaohong I., Frenzel, Martin, Huang, Yu-Jing, Dickler, Maura N., Tolaney, Sara M.
Formato: Artigo
Idioma:Inglês
Publicado: Springer US 2020
Assuntos:
Clinical Trial
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7568708/
https://ncbi.nlm.nih.gov/pubmed/32789591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05838-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares